A Phase I Study of Dexmedetomidine Bolus and Infusion in Corrective Infant Cardiac Surgery: Safety and Pharmacokinetics
Status: | Completed |
---|---|
Conditions: | Cardiology, Cardiology, Cardiology |
Therapuetic Areas: | Cardiology / Vascular Diseases |
Healthy: | No |
Age Range: | Any |
Updated: | 4/17/2018 |
Start Date: | April 2, 2014 |
End Date: | October 17, 2017 |
The purpose of this Phase I study is to determine the safety of a drug called dexmedetomidine
(DEX) as part of a balanced general anesthetic and sedative strategy for neonates and infants
undergoing corrective cardiac surgery that requires the use of cardiopulmonary bypass for
congenital cardiac problems. This study will also design and validate a dosing schema for the
use of DEX as described above.
(DEX) as part of a balanced general anesthetic and sedative strategy for neonates and infants
undergoing corrective cardiac surgery that requires the use of cardiopulmonary bypass for
congenital cardiac problems. This study will also design and validate a dosing schema for the
use of DEX as described above.
Inclusion Criteria:
1. Male or female, age 0 to 180 days at the time of surgery.
2. Diagnosis of: D-transposition of the great arteries (with or without ventricular
septal defect), or tetralogy of Fallot, or ventricular septal defect (with or without
associated atrial septal defect and/or patent ductus arteriosus)
3. Scheduled for complete corrective two-ventricle surgical repair with cardiopulmonary
bypass.
Exclusion Criteria:
- 1. Less than 37 completed weeks' gestational age at birth for the Neonatal age group
(0-21 days); less than 36 completed weeks' gestational age at birth for the Infant age
group (22-180 days).
2. Enrollment in the PHN Collaborative Learning Study, if tetralogy of Fallot 91-180
days of age only.
3. Known or suspected hepatic dysfunction; AST and ALT >3X upper limit of normal at
the time of screening within 72 hours of operation.
4. Known or suspected renal dysfunction; serum creatinine > 0.8 mg/dL after 7 days of
age, >1.2 mg/dL if <7 days of age, within 72 hours of operation.
5. Preoperative administration of DEX or clonidine within 72 hours of operation.
6. Major congenital anomaly(ies) outside the cardiovascular system that in the
investigator's opinion would potentially affect safety or pharmacokinetics.
7. Preoperative central nervous system injury resulting in clinical signs and
symptoms: coma, seizures, hemiparesis.
8. Planned period of deep hypothermic circulatory arrest. 9. History of second or
third degree heart block. 10. Sinus or junctional bradycardia below 80 BPM sustained
for greater than 15 minutes within 72 hours of operation. 11. Junctional rhythm
sustained for greater than 15 minutes within 72 hours of operation.
12. Hypotension defined as mean arterial blood pressure below 35 mm Hg for 0-21 day
old neonatal patients, and below 40 mm Hg for 22-180 day old infant patients sustained
for greater than 15 minutes within 72 hours of operation.
13. History of cardiac arrest or ECMO cannulation.
We found this trial at
4
sites
Boston Children's Hospital Boston Children's Hospital is a 395-bed comprehensive center for pediatric health care....
Click here to add this to my saved trials
South 34th Street
Philadelphia, Pennsylvania 19104
Philadelphia, Pennsylvania 19104
215-590-1000
Phone: 215-590-1874
Children's Hospital of Philadelphia Since its start in 1855 as the nation's first hospital devoted...
Click here to add this to my saved trials
University of Michigan The University of Michigan was founded in 1817 as one of the...
Click here to add this to my saved trials
6621 Fannin St
Houston, Texas 77030
Houston, Texas 77030
(832) 824-1000
Principal Investigator: Dean B Andropoulos, MD
Phone: 832-826-5822
Texas Children's Hospital Texas Children's Hospital, located in Houston, Texas, is a not-for-profit organization whose...
Click here to add this to my saved trials